00:02 , Mar 7, 2019 |  BC Extra  |  Clinical News

Allergan's rapastinel misses as adjunct depression therapy

Allergan said late Wednesday that rapastinel as adjunctive therapy missed the primary endpoint in three Phase III trials for the acute treatment of major depressive disorder (MDD). Allergan plc (NYSE:AGN) is also conducting a Phase...
01:31 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million on Feb. 26 in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through...
14:01 , Feb 26, 2019 |  BC Extra  |  Financial News

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million Tuesday in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA...
02:03 , Feb 23, 2019 |  BioCentury  |  Product Development

Benchmarks for NASH

Benchmarking clinical value in NASH will require more than the topline data reported this week by Intercept Pharmaceuticals Inc. The readout gained Ocaliva obeticholic acid the title of first NASH therapy to meet in Phase...
00:10 , Feb 20, 2019 |  BC Extra  |  Company News

Management tracks: Allergan, Arix, Quest, SurModics

Allergan plc (NYSE:AGN) appointed Robert Hugin to its board. He stepped down as CEO of Celgene Corp. (NASDAQ: CELG) in 2016, and retired as Celgene's executive chairman last year. Mark Alles is Celgene's current chairman...
19:45 , Feb 15, 2019 |  BC Week In Review  |  Company News

Supreme Court pushes timeline for Tribe, Allergan appeal

The U.S. Supreme Court granted a motion from Mylan N.V. (NASDAQ:MYL) to extend to March 11 from Feb. 11 the deadline for response to a petition for writ of certiorari filed by Allergan plc (NYSE:AGN)...
20:33 , Feb 5, 2019 |  BC Extra  |  Company News

FDA psychiatry product division director joins Allergan

Following a 12-year tenure as director of FDA’s Division of Psychiatry Products, Mitchell Mathis has joined Allergan plc (NYSE:AGN) as CMO for CNS products. Mathis left FDA on Jan. 19 and joined Allergan later in...
00:43 , Jan 30, 2019 |  BC Extra  |  Company News

Allergan sheds $4.5B in market cap on 4Q18 earnings

Allergan plc (NYSE:AGN) lost $13.57 to $145.12 on Tuesday after it reported a $4.3 billion net loss in 4Q18 and presented 1Q19 guidance well below the Street’s consensus. The stock move translates to a loss...
21:42 , Jan 25, 2019 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 15 profitable biotechs and pharmas are slated to report earnings this week. (A) Before U.S. markets open; during trading hours in Europe; (B) Six-month EPS estimate; (C) Fiscal 3Q; (D)...
17:56 , Jan 22, 2019 |  BC Extra  |  Company News

Bosley leaving Editas as CRISPR company moves toward clinic

Editas Medicine Inc. (NASDAQ:EDIT) said Katrine Bosley is stepping down as president and CEO, effective March 1. Cynthia Collins, a director since December, will be interim CEO while the gene editing company searches for a...